Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Birgit Ehlken"'
Autor:
Birgit Ehlken, Chihiro Nishikawa, Sigal Kaplan, Isabelle Dresco, Denis Granados, Massoud Toussi
Publikováno v:
Current Medical Research and Opinion. 38:461-468
Since 2014, valproate has not been recommended for use in girls and women of childbearing potential unless other treatments are ineffective or not tolerated. Risk minimization measures (RMMs) of valproate were implemented to reduce the potential risk
Autor:
Derya Bocuk, Stefan Wohlfeil, Massoud Toussi, Birgit Ehlken, Annegret Gohlke, Lennart Nathell
Publikováno v:
Drug Safety. 42:693-696
Autor:
Dimitri Bennett, Birgit Ehlken, Michie Hisada, Maria Del Pilar Lopez Fuensalida de Torres, Margarita Shlaen
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective To evaluate azilsartan medoxomil (AZM) (Edarbi®) utilization patterns in the primary-care setting in Germany. Materials and methods This is a retrospective cohort study among patients receiving AZM in the primary-care setting in Germany. P
Autor:
Annegret Gohlke, Stefan Wohlfeil, Massoud Toussi, Birgit Ehlken, Lennart Nathell, Derya Bocuk
Publikováno v:
Drug Safety
Introduction Hypersensitivity reactions (HSRs) are among the known adverse events of intravenous (i.v.) iron products. Of these, particularly severe HSRs such as anaphylaxis are of great clinical concern due to their life-threatening potential. Metho
Publikováno v:
Current medical research and opinion. 35(8)
Objectives: This report characterizes flupirtine prescribing patterns before and after the implementation of risk minimization measures (RMM) in Germany as a complementary analysis to suppo...
Autor:
Massoud Toussi, Birgit Ehlken, Denis Granados, Irena Stevanovic, Isabelle Dresco, Sigal Kaplan
Publikováno v:
Revista de Neurología. 73:373
INTRODUCTION Risk minimisation measures for valproate were implemented in Spain in 2015. OBJECTIVE The objective of this study is to assess the effectiveness of valproate risk minimisation measures in Spain intended to decrease the use of valproate a
Autor:
Massoud Toussi, Birgit Ehlken, Rita Silveira Ramos, Abdus Samad, Stella Böhmert, Sigal Kaplan, Mónika Domahidy, Hanka de Voogd, Deepa Arora
Publikováno v:
Journal of clinical pharmacy and therapeutics. 44(3)
What is known and objective The approved indication for trimetazidine (TMZ) was restricted to "add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antiang
Publikováno v:
Current medical research and opinion. 35(1)
Objective: In response to safety concerns, risk minimization measures (RMM) for flupirtine were implemented in Europe in 2013 to reduce hepatotoxicity risk. This study aims to characterize compliance and prescribing practices of flupirtine before and
Publikováno v:
International Journal of Cardiology. 203:882-884
Autor:
Karin Berger, C. de Moor, Birgit Ehlken, C. Schroeder, Jerzy E. Tyczynski, J. Driedger, L. Hofmann-Xu, G. Paulus, J. Clune
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 17(7)